Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. 2010

S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
Medizinische Klinik II, Klinikum der J.W. Goethe-Universität, Frankfurt am Main, Germany. sabine.mousset@kgu.de

Antifungal prophylaxis with posaconazole (POS) has been shown to decrease the mortality associated with invasive fungal infections in high-risk patients. We report on a patient, with severe graft-versus-host disease after allogeneic stem cell transplantation, who developed proven pneumonia due to Rhizopus microsporus after 40 days of POS prophylaxis (fasting serum levels: 691-904 ng/mL). Despite combination treatment with liposomal amphotericin B and POS for 39 days, the patient died from pulmonary hemorrhage. This case highlights the need for continued awareness of breakthrough zygomycosis in patients receiving POS.

UI MeSH Term Description Entries
D008172 Lung Diseases, Fungal Pulmonary diseases caused by fungal infections, usually through hematogenous spread. Fungal Lung Diseases,Pulmonary Fungal Infections,Pulmonary Fungal Diseases,Fungal Disease, Pulmonary,Fungal Diseases, Pulmonary,Fungal Infection, Pulmonary,Fungal Infections, Pulmonary,Fungal Lung Disease,Lung Disease, Fungal,Pulmonary Fungal Disease,Pulmonary Fungal Infection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009091 Mucormycosis Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION. Mucorales Infection,Mucorales Infections,Mucormycoses,Infection, Mucorales,Mucormycose
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
October 2008, Bone marrow transplantation,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
October 2013, Transplant infectious disease : an official journal of the Transplantation Society,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
April 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
February 2016, Medical mycology,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
August 2014, Antimicrobial agents and chemotherapy,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
September 2006, Mycoses,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
January 2007, Antimicrobial agents and chemotherapy,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
January 2004, Bone marrow transplantation,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
February 2002, Leukemia & lymphoma,
S Mousset, and G Bug, and W J Heinz, and K Tintelnot, and V Rickerts
May 2022, BMC infectious diseases,
Copied contents to your clipboard!